AAAAAA

   
Results: 1-25 | 26-50 | 51-58
Results: 1-25/58
CA-125 ELEVATIONS IN PATIENTS WITH MALIGNANT-LYMPHOMAS
Authors: FEHM T BECK E VALERIUS T GRAMATZKI M JAGER W
Citation: T. Fehm et al., CA-125 ELEVATIONS IN PATIENTS WITH MALIGNANT-LYMPHOMAS, Tumor biology, 19(4), 1998, pp. 283-289
ANTIBODIES TC-12 (UNIQUE) AND TH-111 (CD96) CHARACTERIZE T-CELL ACUTELYMPHOBLASTIC-LEUKEMIA AND A SUBGROUP OF ACUTE MYELOID-LEUKEMIA
Authors: GRAMATZKI M LUDWIG WD BURGER R MOOS P ROHWER P GRUNERT C SENDLER A KALDEN JR ANDREESEN R HENSCHKE F MOLDENHAUER G
Citation: M. Gramatzki et al., ANTIBODIES TC-12 (UNIQUE) AND TH-111 (CD96) CHARACTERIZE T-CELL ACUTELYMPHOBLASTIC-LEUKEMIA AND A SUBGROUP OF ACUTE MYELOID-LEUKEMIA, Experimental hematology, 26(13), 1998, pp. 1209-1214
AUTOLOGOUS PBPCT IN A PATIENT WITH LYMPHOMA AND SJOGRENS-SYNDROME - COMPLETE REMISSION OF LYMPHOMA WITHOUT CONTROL OF THE AUTOIMMUNE-DISEASE
Authors: ROSLER W MANGER B REPP R KALDEN JR GRAMATZKI M
Citation: W. Rosler et al., AUTOLOGOUS PBPCT IN A PATIENT WITH LYMPHOMA AND SJOGRENS-SYNDROME - COMPLETE REMISSION OF LYMPHOMA WITHOUT CONTROL OF THE AUTOIMMUNE-DISEASE, Bone marrow transplantation, 22(2), 1998, pp. 211-213
AUTOLOGOUS BMT PBSCT IN PATIENTS WITH BCR-ABL-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA/
Authors: MARTIN H ATTA J FAUTH F OTTMANN OG OTT MG WASSMANN B BERGMANN L KNAUF W GRAMATZKI M ZANDER A BUNJES D ARNOLD R HOELZER D
Citation: H. Martin et al., AUTOLOGOUS BMT PBSCT IN PATIENTS WITH BCR-ABL-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA/, Bone marrow transplantation, 21, 1998, pp. 5-5
REVERSAL OF FACTOR-V DEFICIENCY IN CML DURING ALLOGENEIC PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION
Authors: ROSLER W NEIDHARDT B SALINGER R ECKSTEIN R KALDEN JR GRAMATZKI M
Citation: W. Rosler et al., REVERSAL OF FACTOR-V DEFICIENCY IN CML DURING ALLOGENEIC PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION, Bone marrow transplantation, 21, 1998, pp. 285-285
EVALUATING ANTIBODIES FOR THEIR CAPACITY TO INDUCE CELL-MEDIATED LYSIS OF MALIGNANT B-CELLS
Authors: WURFLEIN D DECHANT M STOCKMEYER B TUTT AL HU PS REPP R KALDEN JR VANDEWINKEL JGJ EPSTEIN AL VALERIUS T GLENNIE M GRAMATZKI M
Citation: D. Wurflein et al., EVALUATING ANTIBODIES FOR THEIR CAPACITY TO INDUCE CELL-MEDIATED LYSIS OF MALIGNANT B-CELLS, Cancer research, 58(14), 1998, pp. 3051-3058
ACTIVATING RAS-MUTATION OCCURS IN AN IL-6 DEPENDENT MYELOMA CELL-LINE
Authors: GUENTHER A SCHMALZING M KARRASCH M BAKKER F BURGER R GRAMATZKI M
Citation: A. Guenther et al., ACTIVATING RAS-MUTATION OCCURS IN AN IL-6 DEPENDENT MYELOMA CELL-LINE, British Journal of Haematology, 102(1), 1998, pp. 346-347
HUMAN-HERPESVIRUS TYPE-8 INTERLEUKIN-6 HOMOLOG IS FUNCTIONALLY ACTIVEON HUMAN MYELOMA CELLS
Authors: BURGER R NEIPEL F FLECKENSTEIN B SAVINO R CILIBERTO G KALDEN JR GRAMATZKI M
Citation: R. Burger et al., HUMAN-HERPESVIRUS TYPE-8 INTERLEUKIN-6 HOMOLOG IS FUNCTIONALLY ACTIVEON HUMAN MYELOMA CELLS, Blood, 91(6), 1998, pp. 1858-1863
HLA CLASS-II ANTIBODIES RECRUIT G-CSF ACTIVATED NEUTROPHILS FOR TREATMENT OF B-CELL MALIGNANCIES
Authors: VALERIUS T ELSASSER D REPP R VANDEWINKEL JGJ GRAMATZKI M GLENNIE M
Citation: T. Valerius et al., HLA CLASS-II ANTIBODIES RECRUIT G-CSF ACTIVATED NEUTROPHILS FOR TREATMENT OF B-CELL MALIGNANCIES, Leukemia & lymphoma, 26(3-4), 1997, pp. 261
AN IN-VIVO MODEL FOR MULTIPLE-MYELOMA
Authors: GRAMATZKI M BURGER R KUCHER S STEININGER H BAUM W
Citation: M. Gramatzki et al., AN IN-VIVO MODEL FOR MULTIPLE-MYELOMA, European journal of cancer, 33, 1997, pp. 392-392
BISPECIFIC ANTIBODY MDX210 (FC-GAMMA-RI X HER-2 NEU) IN COMBINATION WITH G-CSF - RESULTS OF A PHASE-I TRIAL IN PATIENTS WITH METASTATIC BREAST-CANCER/
Authors: VALERIUS T STOCKMEYER B REPP R DEO Y VANOIJK H VANDEWINKEL JG KALDEN JR GRAMATZKI M
Citation: T. Valerius et al., BISPECIFIC ANTIBODY MDX210 (FC-GAMMA-RI X HER-2 NEU) IN COMBINATION WITH G-CSF - RESULTS OF A PHASE-I TRIAL IN PATIENTS WITH METASTATIC BREAST-CANCER/, European journal of cancer, 33, 1997, pp. 676-676
GROWTH OF AN INTERLEUKIN-6 DEPENDENT CELL-LINE IN THE SCID MOUSE GIVES RISE TO TUMORS WITH DISTINCT CYTOKINE RESPONSE PATTERNS
Authors: BURGER R KUCHER S STEININGER H BAUM W GRAMATZKI M
Citation: R. Burger et al., GROWTH OF AN INTERLEUKIN-6 DEPENDENT CELL-LINE IN THE SCID MOUSE GIVES RISE TO TUMORS WITH DISTINCT CYTOKINE RESPONSE PATTERNS, Experimental hematology, 25(8), 1997, pp. 219-219
FC-ALPHA-RI (CD89) AS A NOVEL CYTOTOXIC TRIGGER MOLECULE FOR BISPECIFIC ANTIBODIES
Authors: STOCKMEYER B VALERIUS T REPP R DEO Y VANSPIEK A KALDEN JR VANDEWINKEL JGJ GRAMATZKI M
Citation: B. Stockmeyer et al., FC-ALPHA-RI (CD89) AS A NOVEL CYTOTOXIC TRIGGER MOLECULE FOR BISPECIFIC ANTIBODIES, Experimental hematology, 25(8), 1997, pp. 560-560
GERMAN CONSENSUS ON IMMUNOGENETIC DONOR SEARCH FOR TRANSPLANTATION OFALLOGENEIC BONE-MARROW AND PERIPHERAL-BLOOD STEM-CELLS
Authors: OTTINGER HD ALBERT E ARNOLD R BEELEN DW BLASCZYK R BUNJES D BURDACH S EBELL W EHNINGER G EINSELE H ENCZMANN J FAUSER A FRIEDRICH W FINKE J GOBEL U GOLDMANN SF GRAMATZKI M HELBIG W KANZ L KLINGSBIEL T KOLB HJ KUHNL P LOLIGER C MULLER CR MULLER CA NIETHAMMER D SCHAEFER UW SAYER H SCHMITZ N SCHULZERATH R WASSMUTH R WERNET P WESTPHAL E ZANDER R ZINTL F GROSSEWILDE H
Citation: Hd. Ottinger et al., GERMAN CONSENSUS ON IMMUNOGENETIC DONOR SEARCH FOR TRANSPLANTATION OFALLOGENEIC BONE-MARROW AND PERIPHERAL-BLOOD STEM-CELLS, Bone marrow transplantation, 20(2), 1997, pp. 101-105
ANTIBODIES AS SPECIFIC ANTICANCER AGENTS - WISHFUL THINKING OR REAL POSSIBILITY
Authors: GRAMATZKI M VALERIUS T
Citation: M. Gramatzki et T. Valerius, ANTIBODIES AS SPECIFIC ANTICANCER AGENTS - WISHFUL THINKING OR REAL POSSIBILITY, Der Internist, 38(11), 1997, pp. 1055-1062
PRECLINICAL STUDIES WITH FC-GAMMA-R BISPECIFIC ANTIBODIES AND GRANULOCYTE-COLONY-STIMULATING FACTOR-PRIMED NEUTROPHILS AS EFFECTOR-CELLS AGAINST HER-2 NEU OVEREXPRESSING BREAST-CANCER/
Authors: STOCKMEYER B VALERIUS T REPP R HEIJNEN IAFM BUHRING HJ DEO YM KALDEN JR GRAMATZKI M VANDEWINKEL JGJ
Citation: B. Stockmeyer et al., PRECLINICAL STUDIES WITH FC-GAMMA-R BISPECIFIC ANTIBODIES AND GRANULOCYTE-COLONY-STIMULATING FACTOR-PRIMED NEUTROPHILS AS EFFECTOR-CELLS AGAINST HER-2 NEU OVEREXPRESSING BREAST-CANCER/, Cancer research, 57(4), 1997, pp. 696-701
FC-ALPHA-RI (CD89) AS A NOVEL TRIGGER MOLECULE FOR BISPECIFIC ANTIBODY THERAPY
Authors: VALERIUS T STOCKMEYER B VANSPRIEL AB GRAZIANO RF VANDENHERIKOUDIJK IE REPP R DEO YM LUND J KALDEN JR GRAMATZKI M VANDEWINKEL JGJ
Citation: T. Valerius et al., FC-ALPHA-RI (CD89) AS A NOVEL TRIGGER MOLECULE FOR BISPECIFIC ANTIBODY THERAPY, Blood, 90(11), 1997, pp. 4485-4492
FC-ALPHA-RI (CD89) AS A NOVEL TRIGGER MOLECULE FOR BISPECIFIC ANTIBODY THERAPY
Authors: VALERIUS T STOCKMEYER B VANSPRIEL AB GRAZIANO RF VANDENHERIKOUDIJK IE REPP R DEO YM KALDEN JR VANDEWINKEL JGJ GRAMATZKI M
Citation: T. Valerius et al., FC-ALPHA-RI (CD89) AS A NOVEL TRIGGER MOLECULE FOR BISPECIFIC ANTIBODY THERAPY, Blood, 90(10), 1997, pp. 2927-2927
HAMMERHEAD RIBOZYMES AGAINST RAS-MUTATIONS IN MULTIPLE-MYELOMA
Authors: GUENTHER A SCHMALZING M BURGER R GRAMATZKI M KALDEN JR
Citation: A. Guenther et al., HAMMERHEAD RIBOZYMES AGAINST RAS-MUTATIONS IN MULTIPLE-MYELOMA, Blood, 90(10), 1997, pp. 4094-4094
HUMAN-HERPESVIRUS TYPE-8 (HHV-8) INTERLEUKIN-6 HOMOLOG IS FUNCTIONALLY ACTIVE ON HUMAN MYELOMA CELLS
Authors: GRAMATZKI M BURGER R NEIPEL F FLECKENSTEIN B
Citation: M. Gramatzki et al., HUMAN-HERPESVIRUS TYPE-8 (HHV-8) INTERLEUKIN-6 HOMOLOG IS FUNCTIONALLY ACTIVE ON HUMAN MYELOMA CELLS, Blood, 90(10), 1997, pp. 378-378
JAK-2 INHIBITOR TYRPHOSTIN AG490 INHIBITS IL-6 DEPENDENT PROLIFERATION OF A MYELOMA CELL-LINE
Authors: BURGER R PIEKORZ R HOCKE G GRAMATZKI M
Citation: R. Burger et al., JAK-2 INHIBITOR TYRPHOSTIN AG490 INHIBITS IL-6 DEPENDENT PROLIFERATION OF A MYELOMA CELL-LINE, Blood, 90(10), 1997, pp. 2342-2342
CONSENSUS PROTOCOL FOR THE FLOW CYTOMETRIC IMMUNOPHENOTYPING OF HEMATOPOIETIC MALIGNANCIES
Authors: ROTHE G SCHMITZ G ADORF D BARLAGE S GRAMATZKI M HANENBERG H HOFFKES HG JANOSSY G KNUCHEL R LUDWIG WD NEBE T NERL C ORFAO A SERKE S SONNEN R TICHELLI A WORMANN B
Citation: G. Rothe et al., CONSENSUS PROTOCOL FOR THE FLOW CYTOMETRIC IMMUNOPHENOTYPING OF HEMATOPOIETIC MALIGNANCIES, Leukemia, 10(5), 1996, pp. 877-895
INTENSIVE POSTREMISSION THERAPY IN ACUTE MYELOID-LEUKEMIA - RESULTS OF A PROSPECTIVE COMPARATIVE TRIAL
Authors: HUBNER G LINK H SCHONROCKNABULSI P WANDT H GRAMATZKI M LOFFLER B FACKLERSCHWALBE I QUEISSER W BRACK N GEER T RAAB M OHL S SCHNEIDER B SCHNEIDER C FREUND M POLIWODA H EHNINGER G
Citation: G. Hubner et al., INTENSIVE POSTREMISSION THERAPY IN ACUTE MYELOID-LEUKEMIA - RESULTS OF A PROSPECTIVE COMPARATIVE TRIAL, Medizinische Klinik, 91, 1996, pp. 26-32
THERAPY WITH AZT AND INTRALYMPHATIC NATURAL INTERLEUKIN-2 (NIL-2) IN PATIENTS WITH AIDS
Authors: HARRER T SCHWAB J STRUFF WG SCHMITT M FICKER J RODL W PARSCH D KALDEN JR GRAMATZKI M
Citation: T. Harrer et al., THERAPY WITH AZT AND INTRALYMPHATIC NATURAL INTERLEUKIN-2 (NIL-2) IN PATIENTS WITH AIDS, AIDS, 10, 1996, pp. 65-65
THERAPY WITH CD7 MONOCLONAL-ANTIBODY TH-69 IS HIGHLY EFFECTIVE FOR XENOGRAFTED HUMAN T-CELL ALL
Authors: BAUM W STEININGER H BAIR HJ BECKER W HANSENHAGGE TE KRESSEL M KREMMER E KALDEN JR GRAMATZKI M
Citation: W. Baum et al., THERAPY WITH CD7 MONOCLONAL-ANTIBODY TH-69 IS HIGHLY EFFECTIVE FOR XENOGRAFTED HUMAN T-CELL ALL, British Journal of Haematology, 95(2), 1996, pp. 327-338
Risultati: 1-25 | 26-50 | 51-58